Nucs AI and AstraZeneca Collaborate on AI Response Prediction for Radioconjugate Research
Nucs AI has announced a collaboration with AstraZeneca to develop AI models that predict patient response to PSMA-targeted radioconjugate therapies for metastatic prostate cancer.